Lv1
20 积分 2024-10-06 加入
Risankizumab for Ulcerative Colitis
29天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
1个月前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
1个月前
已完结
皖公网安备34019202002308
